Daniel J. Moorhead Sells 10,000 Shares of Zynex, Inc. (NASDAQ:ZYXI) Stock

Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead sold 10,000 shares of the business’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $7.68, for a total transaction of $76,800.00. Following the sale, the chief financial officer now owns 19,738 shares of the company’s stock, valued at approximately $151,587.84. This represents a 33.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Zynex Stock Performance

Shares of NASDAQ:ZYXI traded down $0.11 during midday trading on Monday, hitting $7.73. The company had a trading volume of 68,172 shares, compared to its average volume of 59,099. Zynex, Inc. has a 12-month low of $7.15 and a 12-month high of $13.77. The company has a fifty day moving average of $8.11 and a two-hundred day moving average of $8.20. The company has a market cap of $246.20 million, a price-to-earnings ratio of 51.53 and a beta of 0.54. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.94 and a quick ratio of 3.15.

Institutional Trading of Zynex

Hedge funds and other institutional investors have recently bought and sold shares of the stock. R Squared Ltd bought a new position in Zynex in the 4th quarter worth $26,000. Gladius Capital Management LP boosted its stake in shares of Zynex by 53.4% in the third quarter. Gladius Capital Management LP now owns 5,002 shares of the company’s stock worth $41,000 after acquiring an additional 1,742 shares during the period. Investment Partners Asset Management Inc. purchased a new stake in shares of Zynex during the third quarter worth about $96,000. Hsbc Holdings PLC bought a new stake in Zynex during the 2nd quarter valued at approximately $113,000. Finally, Jane Street Group LLC raised its stake in Zynex by 8.9% during the 3rd quarter. Jane Street Group LLC now owns 23,530 shares of the company’s stock valued at $192,000 after purchasing an additional 1,929 shares during the period. Hedge funds and other institutional investors own 29.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on ZYXI shares. Royal Bank of Canada reduced their price objective on Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $17.00 price objective on shares of Zynex in a report on Friday, December 6th.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.